FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904320752> ?p ?o ?g. }

• W2904320752 endingPage "891" @default.
• W2904320752 startingPage "884" @default.
• W2904320752 abstract "Combined BRAF and MEK inhibition (BRAF-MEK) is a standard therapy for patients with BRAF V600-mutant melanoma, but to the authors' knowledge, the tolerance, adverse event (AE) profile, and efficacy have not been well defined in the post-programmed cell death protein 1 (PD-1) setting.Patients with BRAF V600-mutant melanoma who received combined BRAF-MEK after prior PD-1-based therapy were assembled from 4 tertiary care centers in the United States and Australia. Dose modification was defined as a treatment break, dose reduction, or intermittent dosing. Rates of hospitalization and discontinuation due to AEs were collected, and overall survival (OS) was calculated using Kaplan-Meier methods from the time of the initiation of BRAF-MEK therapy.A total of 78 patients were identified as having received a BRAF-MEK regimen at a median of 34 days after the last dose of PD-1-based therapy. The majority of patients (86%) received the combination of dabrafenib and trametinib. Approximately 80% of patients had American Joint Committee on Cancer M1c or M1d disease. Sixty-five regimens (83%) had ≥1 dose modification. The median time to the first dose modification was 14 days; 86% occurred within 90 days and 71% involved pyrexia. Dose modifications were more common in patients receiving BRAF-MEK <90 days after the last dose of PD-1 and who were not receiving steroids. Of the dose modifications, 25 (31%) led to an AE-related hospitalization. Among 55 BRAF-naive patients, the median time receiving BRAF-MEK therapy was 5.8 months and the median OS was 15.6 months.The majority of patients receiving BRAF-MEK inhibition after PD-1 therapy require dose interruptions, and a significant minority require hospitalization for AEs. In this higher risk population, the median time receiving therapy and OS may be inferior to those presented in published phase 3 trials." @default.
• W2904320752 created "2018-12-22" @default.
• W2904320752 creator A5008479799 @default.
• W2904320752 creator A5021765564 @default.
• W2904320752 creator A5022520811 @default.
• W2904320752 creator A5022927802 @default.
• W2904320752 creator A5025067315 @default.
• W2904320752 creator A5040291209 @default.
• W2904320752 creator A5065473791 @default.
• W2904320752 creator A5081603469 @default.
• W2904320752 creator A5083431383 @default.
• W2904320752 creator A5089223773 @default.
• W2904320752 creator A5090268681 @default.
• W2904320752 date "2018-12-06" @default.
• W2904320752 modified "2023-10-16" @default.
• W2904320752 title "Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy" @default.
• W2904320752 cites W1965370740 @default.
• W2904320752 cites W1967551644 @default.
• W2904320752 cites W2010121426 @default.
• W2904320752 cites W2040956995 @default.
• W2904320752 cites W2117138659 @default.
• W2904320752 cites W2121545342 @default.
• W2904320752 cites W2128035403 @default.
• W2904320752 cites W2150669821 @default.
• W2904320752 cites W2152897456 @default.
• W2904320752 cites W2160766792 @default.
• W2904320752 cites W2299181842 @default.
• W2904320752 cites W2491982852 @default.
• W2904320752 cites W2549612601 @default.
• W2904320752 cites W2560367415 @default.
• W2904320752 cites W2605630889 @default.
• W2904320752 cites W2608329604 @default.
• W2904320752 cites W2620651944 @default.
• W2904320752 cites W2745671375 @default.
• W2904320752 cites W2749408522 @default.
• W2904320752 cites W2753432434 @default.
• W2904320752 cites W2762161610 @default.
• W2904320752 cites W2790692623 @default.
• W2904320752 cites W2793817570 @default.
• W2904320752 cites W2800368813 @default.
• W2904320752 cites W2809417568 @default.
• W2904320752 cites W2887127301 @default.
• W2904320752 doi "https://doi.org/10.1002/cncr.31889" @default.
• W2904320752 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8074192" @default.
• W2904320752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30521084" @default.
• W2904320752 hasPublicationYear "2018" @default.
• W2904320752 type Work @default.
• W2904320752 sameAs 2904320752 @default.
• W2904320752 citedByCount "39" @default.
• W2904320752 countsByYear W29043207522019 @default.
• W2904320752 countsByYear W29043207522020 @default.
• W2904320752 countsByYear W29043207522021 @default.
• W2904320752 countsByYear W29043207522022 @default.
• W2904320752 countsByYear W29043207522023 @default.
• W2904320752 crossrefType "journal-article" @default.
• W2904320752 hasAuthorship W2904320752A5008479799 @default.
• W2904320752 hasAuthorship W2904320752A5021765564 @default.
• W2904320752 hasAuthorship W2904320752A5022520811 @default.
• W2904320752 hasAuthorship W2904320752A5022927802 @default.
• W2904320752 hasAuthorship W2904320752A5025067315 @default.
• W2904320752 hasAuthorship W2904320752A5040291209 @default.
• W2904320752 hasAuthorship W2904320752A5065473791 @default.
• W2904320752 hasAuthorship W2904320752A5081603469 @default.
• W2904320752 hasAuthorship W2904320752A5083431383 @default.
• W2904320752 hasAuthorship W2904320752A5089223773 @default.
• W2904320752 hasAuthorship W2904320752A5090268681 @default.
• W2904320752 hasBestOaLocation W29043207521 @default.
• W2904320752 hasConcept C11960822 @default.
• W2904320752 hasConcept C126322002 @default.
• W2904320752 hasConcept C143998085 @default.
• W2904320752 hasConcept C185592680 @default.
• W2904320752 hasConcept C197934379 @default.
• W2904320752 hasConcept C2776131300 @default.
• W2904320752 hasConcept C2777658100 @default.
• W2904320752 hasConcept C2778472372 @default.
• W2904320752 hasConcept C2778715236 @default.
• W2904320752 hasConcept C2778830669 @default.
• W2904320752 hasConcept C2781249067 @default.
• W2904320752 hasConcept C2781413609 @default.
• W2904320752 hasConcept C2994587330 @default.
• W2904320752 hasConcept C502942594 @default.
• W2904320752 hasConcept C55493867 @default.
• W2904320752 hasConcept C57074206 @default.
• W2904320752 hasConcept C71924100 @default.
• W2904320752 hasConceptScore W2904320752C11960822 @default.
• W2904320752 hasConceptScore W2904320752C126322002 @default.
• W2904320752 hasConceptScore W2904320752C143998085 @default.
• W2904320752 hasConceptScore W2904320752C185592680 @default.
• W2904320752 hasConceptScore W2904320752C197934379 @default.
• W2904320752 hasConceptScore W2904320752C2776131300 @default.
• W2904320752 hasConceptScore W2904320752C2777658100 @default.
• W2904320752 hasConceptScore W2904320752C2778472372 @default.
• W2904320752 hasConceptScore W2904320752C2778715236 @default.
• W2904320752 hasConceptScore W2904320752C2778830669 @default.
• W2904320752 hasConceptScore W2904320752C2781249067 @default.
• W2904320752 hasConceptScore W2904320752C2781413609 @default.
• W2904320752 hasConceptScore W2904320752C2994587330 @default.
• W2904320752 hasConceptScore W2904320752C502942594 @default.

• next